Akero Therapeutics Inc
AKRO48.610USD
+0.240+0.50%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.87BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Akero Therapeutics Inc Unternehmen
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Unternehmensinformationen
BörsenkürzelAKRO
Name des UnternehmensAkero Therapeutics Inc
IPO-datumJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Anzahl der mitarbeiter63
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse601 Gateway Boulevard, Suite 350
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504876488
Websitehttps://akerotx.com/
BörsenkürzelAKRO
IPO-datumJun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
306.19K
-8.92%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
192.48K
-1.56%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
25.61K
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
9.40K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.31%
Janus Henderson Investors
8.87%
Wellington Management Company, LLP
7.45%
BlackRock Institutional Trust Company, N.A.
6.88%
General Atlantic LLC
6.57%
Other
60.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
45.11%
Investment Advisor
32.34%
Hedge Fund
15.98%
Private Equity
8.24%
Research Firm
3.82%
Venture Capital
2.68%
Individual Investor
1.28%
Foundation
0.41%
Pension Fund
0.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
489
88.09M
110.50%
+677.60K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
2023Q1
350
52.43M
112.99%
-8.33M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RTW Investments L.P.
7.42M
9.31%
+559.52K
+8.16%
Mar 31, 2025
Janus Henderson Investors
7.07M
8.87%
+1.03M
+17.14%
Mar 31, 2025
Wellington Management Company, LLP
5.94M
7.45%
-1.44M
-19.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
6.88%
+346.72K
+6.75%
Mar 31, 2025
General Atlantic LLC
5.23M
6.57%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
4.73M
5.94%
+490.10K
+11.55%
Mar 31, 2025
The Vanguard Group, Inc.
4.22M
5.29%
+526.23K
+14.25%
Mar 31, 2025
Deep Track Capital LP
3.21M
4.03%
+1.72M
+115.45%
Mar 31, 2025
State Street Global Advisors (US)
2.49M
3.13%
+158.80K
+6.80%
Mar 31, 2025
UBS Financial Services, Inc.
2.16M
2.71%
+1.78M
+479.92%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Simplify Propel Opportunities ETF
11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
2.99%
ALPS Medical Breakthroughs ETF
2.87%
SPDR S&P Biotech ETF
1.26%
Tema Heart & Health ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
First Trust NASDAQ Pharmaceuticals ETF
0.6%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
Mehr Anzeigen
Simplify Propel Opportunities ETF
Anteil11.49%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.99%
ALPS Medical Breakthroughs ETF
Anteil2.87%
SPDR S&P Biotech ETF
Anteil1.26%
Tema Heart & Health ETF
Anteil1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.9%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.72%
First Trust NASDAQ Pharmaceuticals ETF
Anteil0.6%
Invesco Nasdaq Biotechnology ETF
Anteil0.47%
ProShares Ultra Nasdaq Biotechnology
Anteil0.47%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
